- Phosphine-catalyzed Aza-MBH reactions of vinylpyridines: Efficient and rapid access to 2,3,5-triarylsubstituted 3-pyrrolines
-
Vinylpyridines have been developed in aza-Morita-Baylis-Hillman (MBH) reaction to construct triarylsubstituted 3-pyrrolines. The first electron-deficient aromatic ring is marked as an activating mode for the vinyl group in the MBH reaction. This method provides efficient and rapid access to a range of triarylpyrrolines in good yields and at an excellent level of diastereoselectivity. Moreover, the synthetic potential of this protocol is further enhanced by the straightforward synthesis of unsymmetrical tri- and polyarylsubstituted pyrroles.
- Chen, Jing,Li, Jianjun,Wang, Jiazhe,Li, Hao,Wang, Wei,Guo, Yuewei
-
-
Read Online
- Organocatalytic enantioselective direct additions of aldehydes to 4-vinylpyridines and electron-deficient vinylarenes and their synthetic applications
-
We describe a synergistic catalysis strategy for the asymmetric direct addition of simple aldehydes to 4-vinylpyridines. By means of independent activation of weakly electrophilic 4-vinylpyridines by the Bronsted acid CF3SO3H (TfOH) and aldehydes by chiral diphenylprolinol tert-butyldimethylsilyl (TBDMS) ether-catalyzed formation of nucleophilic enamines in a cooperative manner, the previously unattainable highly enantioselective addition process has been realized for the first time. Notably, the power of the addition process is fueled by its high efficiency in the production of synthetically valued chiral pyridines. 1H NMR studies of the process suggested that the nucleophilic enamine formed in situ from the chiral amine catalyst and the aldehyde is directly added to the trimeric 4-vinylpyridinium-derived species as a highly active electrophile generated from the 4-vinylpyridine in the presence of TfOH. Moreover, inspired by the similar electronic natures of pyridine and nitrobenzene, we have achieved an unprecedented chiral diphenylprolinol TBDMS ether-promoted, highly enantioselective direct addition of aldehydes to 2-nitrostyrenes without the use of TfOH as a cocatalyst. In this approach, introducing a strong electron-withdrawing group such as NO2, CF3, SO2Me, etc. on the 2-nitrostyrene creates a highly electrophilic vinyl moiety, which enables the direct addition of the in situ-formed enamine derived from the chiral amine promoter and the aldehyde. This method significantly expands the scope of the enantioselective addition process. While the electron-withdrawing nitro group is essential for activation of the vinyl group, we have demonstrated that it can be readily transformed to diverse functionalities. Furthermore, as shown, a chiral pyridine adduct serves as a key building block in the synthesis of the potent fibrinogen receptor antagonist L-734,217.
- Wang, Sinan,Li, Xiangmin,Liu, Hongwei,Xu, Li,Zhuang, Jinchen,Li, Jian,Li, Hao,Wang, Wei
-
supporting information
p. 2303 - 2310
(2015/03/04)
-
- SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS
-
The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
- -
-
-
- Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
-
Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.
- -
-
-
- Substituted Heterocyclic Aza Compounds
-
Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.
- -
-
Paragraph 0824
(2013/03/26)
-
- SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES
-
The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
- -
-
Page/Page column 146
(2013/03/26)
-
- Ring-closing metathesis reactions on azinium salts: Straightforward access to quinolizinium cations and their dihydro derivatives
-
(Chemical Equation Presented) The ring-closing metathesis reaction of 1-butenyl-2-vinylpyridinium salts and 2-butenyl-1-vinylpyridinium salts using Grubbs second generation and Hoveyda-Grubbs catalysts proved to be an efficient approach to 3,4-dihydro- and 1,2-dihydroquinolizinium salts and the corresponding quinolizinium derivatives by an improved thermal oxidation in the presence of Pd/C without solvent. A comparative study showed that the quinolizinium system was obtained in better yields through the 3,4-dihydroquinolizinium route, thus allowing the synthesis of quinolizinium derivatives or improvements in the yields of some examples reported previously.
- Nunez, Ana,Abarca, Beatriz,Cuadro, Ana M.,Alvarez-Builla, Julio,Vaquero, Juan J.
-
scheme or table
p. 4166 - 4176
(2009/09/08)
-
- THIAZOLE AND OXAZOLE KINASE INHIBITORS
-
The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
- -
-
Page/Page column 156
(2009/04/25)
-
- HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
-
The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6- alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- -membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
- -
-
Page/Page column 122-123
(2010/11/08)
-